Prothena Corp PLC (PRTA)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

77 SIR JOHN ROGERSON'S QUAY, BLOCK C DUBLIN 2, IRELAND D02 VK60

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s partnered programs include prasinezumab (PRX002/RG7935), in collaboration with Roche for the potential treatment of Parkinson’s disease and other related synucleinopathies, and programs that target tau (PRX005), TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) or other neurodegenerative diseases. Prothena’s wholly-owned programs include PRX004 for the potential treatment of ATTR amyloidosis, and a portfolio of programs for the potential treatment of Alzheimer’s disease including PRX012 that targets Aß (Amyloid beta).

Data as of 2021-10-09 09:58:54 -0400
Market Cap3.143 Billion Shares Outstanding44.176 Million Avg 30-day Volume332.902 Thousand
P/E Ratio-44.6553 Dividend Yield0.0 EPS-1.68
Price/Sales51.44 Debt to Equity1.51 EBITDA-58.396 Million
Price to Book Value10.84 Forward PE-25.86 Enterprise Value2.725 Billion
Total Cash399.831 Million Current Debt52.899 Million Gross Profit60.748 Million
BETA1.40967 52-week High/Low79.75 / 10.66 Next Earnings Date2021-11-04 Price to Cash FLow (P/CF) 119.5449
Data provided by IEX Cloud
View SEC Filings from PRTA instead.

View recent insider trading info

Funds Holding PRTA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PRTA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

25 Thousand total shares from 11 transactions

Exercise Derivative Conversion (M)

25 Thousand total shares from 3 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SELKOE DENNIS J.

15,208 2021-10-01 4

KARP CAROL D. CHIEF REGULATORY OFFICER

130,000 2021-10-01 4

SMITH BRANDON S. CHIEF OPERATING OFFICER

  • Officer
25,000 2021-09-29 2

HENNEY CHRISTOPHER S

  • Director
0 2021-07-14 6

ZAGO WAGNER M. CHIEF SCIENTIFIC OFFICER

  • Officer
68,750 2021-06-22 4

ECOR1 CAPITAL, LLC

  • 10% Owner
11,284,280 2021-06-18 7

COLLIER RICHARD T

  • Director
15,000 2021-05-19 2

EKMAN LARS

  • Director
  • CHAIRMAN OF THE BOARD
15,000 2021-05-19 2

COOKE SHANE

  • Director
15,000 2021-05-19 2

HARFSTRAND KARL ANDERS OLOF

  • Director
15,000 2021-05-19 2

COBB PAULA K

  • Director
15,000 2021-05-19 1

PATEL SANJIV

  • Director
30,000 2021-05-19 2

GARREN HIDEKI CHIEF MEDICAL OFFICER

  • Officer
0 2021-04-05 2

NGUYEN TRAN SEE REMARKS

  • Officer
84,000 2021-02-25 2

WALKER KARIN L CHIEF ACCOUNTING OFFICER

  • Officer
28,000 2021-02-25 2

KINNEY GENE G. PRESIDENT AND CEO

  • Officer
300,000 2021-02-25 2

TRIPURANENI RADHIKA CHIEF DEVELOPMENT OFFICER

  • Officer
56,000 2021-02-25 2

MALECEK MICHAEL J SEE REMARKS

  • Officer
56,000 2021-02-25 1

NODELMAN OLEG

  • Director
  • 10% Owner
9,426,640 2019-12-03 0

HOMAN ARTHUR W CHIEF LEGAL OFFICER

  • Officer
2,000 2018-06-21 0

NICKERSON TARA CHIEF BUSINESS OFFICER

  • Officer
2,000 2018-02-21 0

NOONBERG SARAH B. CHIEF MEDICAL OFFICER

  • Officer
0 2017-05-16 0

SCHENK DALE B. PRESIDENT AND CEO

  • Officer
  • Director
14,877 2016-02-24 0

KOLLER MARTIN CHIEF MEDICAL OFFICER

  • Officer
0 2016-02-24 0

MCNINCH DAVID B. CHIEF COMMERCIAL OFFICER

  • Officer
0 2016-02-24 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

SELKOE DENNIS J.

2021-10-01 21:18:16 -0400 2021-10-01 M 5,000 d 11,000 direct

SELKOE DENNIS J.

2021-10-01 21:18:16 -0400 2021-10-01 S 1,300 $67.96 d 4,788 direct yes 0.0279 -3.1939 2.1757 4 -3.1939 6

KARP CAROL D. CHIEF REGULATORY OFFICER

2021-10-01 20:46:58 -0400 2021-10-01 M 10,000 d 130,000 direct

KARP CAROL D. CHIEF REGULATORY OFFICER

2021-10-01 20:46:58 -0400 2021-10-01 S 1,967 $68.68 d 2,813 direct yes 0.0279 -3.1939 2.1757 4 -3.1939 6

KARP CAROL D. CHIEF REGULATORY OFFICER

2021-10-01 20:46:58 -0400 2021-10-01 M 10,000 $15.04 a 10,000 direct 0.0279 -3.1939 2.1757 4 -3.1939 6

SELKOE DENNIS J.

2021-10-01 21:18:16 -0400 2021-10-01 S 706 $69.69 d 2,845 direct yes 0.0279 -3.1939 2.1757 4 -3.1939 6

SELKOE DENNIS J.

2021-10-01 21:18:16 -0400 2021-10-01 S 1,757 $66.35 d 6,088 direct yes 0.0279 -3.1939 2.1757 4 -3.1939 6

KARP CAROL D. CHIEF REGULATORY OFFICER

2021-10-01 20:46:58 -0400 2021-10-01 S 213 $70.44 d 0 direct yes 0.0279 -3.1939 2.1757 4 -3.1939 6

KARP CAROL D. CHIEF REGULATORY OFFICER

2021-10-01 20:46:58 -0400 2021-10-01 S 2,620 $67.98 d 4,780 direct yes 0.0279 -3.1939 2.1757 4 -3.1939 6

SELKOE DENNIS J.

2021-10-01 21:18:16 -0400 2021-10-01 S 1,237 $68.74 d 3,551 direct yes 0.0279 -3.1939 2.1757 4 -3.1939 6

SELKOE DENNIS J.

2021-10-01 21:18:16 -0400 2021-10-01 M 5,000 $9.23 a 7,845 direct 0.0279 -3.1939 2.1757 4 -3.1939 6

KARP CAROL D. CHIEF REGULATORY OFFICER

2021-10-01 20:46:58 -0400 2021-10-01 S 2,600 $69.61 d 213 direct yes 0.0279 -3.1939 2.1757 4 -3.1939 6

KARP CAROL D. CHIEF REGULATORY OFFICER

2021-10-01 20:46:58 -0400 2021-10-01 S 2,600 $66.60 d 7,400 direct yes 0.0279 -3.1939 2.1757 4 -3.1939 6

SMITH BRANDON S. - Officer CHIEF OPERATING OFFICER

2021-10-01 16:31:45 -0400 2021-09-29 A 25,000 a 25,000 direct

KARP CAROL D. CHIEF REGULATORY OFFICER

2021-09-10 17:06:07 -0400 2021-09-09 M 10,000 $15.04 a 10,000 direct 2.897 3.2004 6.3181 5 0.0 1

KARP CAROL D. CHIEF REGULATORY OFFICER

2021-09-10 17:06:07 -0400 2021-09-09 S 4,542 $72.63 d 0 direct yes 2.897 3.2004 6.3181 5 0.0 1

KARP CAROL D. CHIEF REGULATORY OFFICER

2021-09-10 17:06:07 -0400 2021-09-09 S 5,458 $71.45 d 4,542 direct yes 2.897 3.2004 6.3181 5 0.0 1

KARP CAROL D. CHIEF REGULATORY OFFICER

2021-09-10 17:06:07 -0400 2021-09-09 M 10,000 d 140,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
PROTHENA CORP PLC PRTA 2021-10-15 22:15:04 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 21:45:03 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 21:15:03 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 20:45:03 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 20:15:03 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 19:45:03 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 19:15:04 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 18:45:03 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 18:15:03 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 17:45:03 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 17:15:03 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 16:45:03 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 16:15:03 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 15:45:03 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 15:15:03 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 14:45:02 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 14:15:03 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 13:45:03 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 13:15:03 UTC -0.3598 0.4298 1800000
PROTHENA CORP PLC PRTA 2021-10-15 12:45:03 UTC -0.3598 0.4298 1800000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments